Net Clinical Benefit

How it works

Comparisons

Background

Evidence quality

Highlighted claims

• Net clinical benefit is defined as the number of potassium-lowering interventions after initial treatment minus the change from baseline serum potassium in mEq/L. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• More negative net clinical benefit values indicate greater efficacy, reflecting larger potassium reduction with fewer additional interventions. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Median net clinical benefit at 6 hours was not statistically different between patiromer and placebo groups (−0.6 vs −0.4, p=0.44). — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• The clinically meaningful threshold for net clinical benefit has not yet been established and requires validation in future studies. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• The net clinical benefit endpoint was first introduced as a post hoc analysis in the REDUCE pilot study. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• The net clinical benefit endpoint was chosen to capture total clinical value rather than potassium concentration alone, since binders are difficult to evaluate against treatments that shift potassium intracellularly. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department